The effects of sh-PRSS22 on the immune evasion in the GC mice model were subsequently explored, and we observed that the sh-PRSS22 treatment could induce the relative CD28, GLUT1, Granzyme B, and TCF-1 mRNA expressions but decrease the relative LAG-3, NR4A, and TIM-3 mRNA expressions in T cells of the GC mice model (Fig. 6A). The gene discussed is SLC2A1; the disease is gastric cancer.